CL2018000566A1 - Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas - Google Patents

Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas

Info

Publication number
CL2018000566A1
CL2018000566A1 CL2018000566A CL2018000566A CL2018000566A1 CL 2018000566 A1 CL2018000566 A1 CL 2018000566A1 CL 2018000566 A CL2018000566 A CL 2018000566A CL 2018000566 A CL2018000566 A CL 2018000566A CL 2018000566 A1 CL2018000566 A1 CL 2018000566A1
Authority
CL
Chile
Prior art keywords
ferric pyrophosphate
kits
methods
soluble solid
formulation
Prior art date
Application number
CL2018000566A
Other languages
English (en)
Inventor
Robert Chioini
Ajay Gupta
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of CL2018000566A1 publication Critical patent/CL2018000566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1666—Apparatus for preparing dialysates by dissolving solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

Se proporciona una formulación en forma de partículas sólidas que comprende pirofosfato férrico soluble y una bolsita que comprende la formulación en forma de partículas sólidas de pirofosfato férrico soluble para su adición a una solución de diálisis. Se divulgan métodos mejorados para administrar pirofosfato férrico soluble que comprende las formulaciones de partículas sólidas y los kits comprendiendo la formulación en forma de partículas sólidas y una formulación de concentrado para diálisis.
CL2018000566A 2015-09-04 2018-03-02 Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas CL2018000566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562214908P 2015-09-04 2015-09-04

Publications (1)

Publication Number Publication Date
CL2018000566A1 true CL2018000566A1 (es) 2018-08-03

Family

ID=56926337

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000566A CL2018000566A1 (es) 2015-09-04 2018-03-02 Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas

Country Status (18)

Country Link
US (1) US11517555B2 (es)
EP (1) EP3344235A1 (es)
JP (1) JP7055738B2 (es)
KR (1) KR20180050346A (es)
CN (1) CN108601738A (es)
AU (1) AU2016315877B2 (es)
BR (1) BR112018004244A2 (es)
CA (1) CA2997328A1 (es)
CL (1) CL2018000566A1 (es)
CO (1) CO2018002421A2 (es)
EA (1) EA201890642A1 (es)
IL (1) IL257796B (es)
MX (1) MX2018002633A (es)
PE (1) PE20181162A1 (es)
PH (1) PH12018500463A1 (es)
SG (1) SG10202107245UA (es)
UA (1) UA124923C2 (es)
WO (1) WO2017040937A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
FR3109734B1 (fr) * 2020-05-04 2025-04-11 Univ Claude Bernard Lyon Système de dialyse pour le traitement du sepsis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
JP3778240B2 (ja) 1998-06-22 2006-05-24 ライオン株式会社 不快な味がマスキングされた造粒組成物及びその製造方法
CA2344548C (en) * 1998-09-18 2007-03-13 Rockwell Medical Technologies, Inc. Method and apparatus for preparing liquid dialysate
CN1313080C (zh) * 2000-04-20 2007-05-02 斯凯伊药品加拿大公司 改进的水不溶性药物粒子的制备方法
WO2002051381A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Substance poreuse et son procede de fabrication
JP2002302435A (ja) 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 多孔性物質およびその製造法
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ATE522151T1 (de) * 2005-07-15 2011-09-15 Unilever Nv Eisen verstärktes lebensmittel und zusatzstoff
US7816404B2 (en) 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
US20120177700A1 (en) 2010-12-27 2012-07-12 Imran Mir A Nanonized Iron Compositions and Methods of Use Thereof
WO2014121155A1 (en) 2013-02-01 2014-08-07 Charak Llc Methods of treating iron deficiency with soluble ferric pyrophosphate

Also Published As

Publication number Publication date
UA124923C2 (uk) 2021-12-15
JP7055738B2 (ja) 2022-04-18
AU2016315877A1 (en) 2018-04-05
IL257796B (en) 2021-09-30
CN108601738A (zh) 2018-09-28
PH12018500463A1 (en) 2018-09-17
KR20180050346A (ko) 2018-05-14
IL257796A (en) 2018-04-30
US20180243256A1 (en) 2018-08-30
MX2018002633A (es) 2019-02-07
SG10202107245UA (en) 2021-08-30
BR112018004244A2 (pt) 2018-09-25
PE20181162A1 (es) 2018-07-19
AU2016315877B2 (en) 2022-05-26
CA2997328A1 (en) 2017-03-09
EA201890642A1 (ru) 2018-10-31
US11517555B2 (en) 2022-12-06
EP3344235A1 (en) 2018-07-11
WO2017040937A1 (en) 2017-03-09
CO2018002421A2 (es) 2018-07-19
JP2018529674A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2014001291A1 (es) Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
CR20150549A (es) Compuestos heterocíclicos y sus usos
UY34262A (es) Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
CL2018000566A1 (es) Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO7240370A2 (es) Forma farmaceútica para la liberación prolongada de sustancias activas
MX374618B (es) Ésteres sulfatados de ácidos oligohidroxicarboxílicos, y uso de los mismos.